Rebecca Bradford

Ms. Rebecca Bradford

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2021 in npj Vaccines
Verified
Journal Article
Open access
PDF file
SFSimon Gordon Paul Funnell
Simon Gordon Paul Funnell
BABabak Afrough
Babak Afrough
JBJohn James Baczenas
John James Baczenas
NBNeil Berry
Neil Berry
KBKevin R Bewley
Kevin R Bewley
Ivana KnezevicIvana Knezevic
Ivana Knezevic
An array of SARS-CoV-2 virus variants have been isolated, propagated and used in in vitro assays, in vivo animal studies and human clinical trials. Observations of working stocks of SARS-CoV-2 suggest that sequential propagation in Vero cells leads to critical changes in the region of the furin cleavage site, which significantly reduce the value of the working stock for critical research studies. Serially propagating SARS-CoV-2 in Vero E6 cells leads to rapid increases in genetic variants while propagation in other cell lines (e.g. Vero/hSLAM) appears to mitigate this risk thereby improving the overall genetic stability of working stocks. From these observations, investigators are urged to monitor genetic variants carefully when propagating SARS-CoV-2 in Vero cells.

4 December 2021 in Viruses
Verified
Journal Article
Open access
PDF file
JBJohn James Baczenas
John James Baczenas
HEHanne Andersen Andersen Elyard
Hanne Andersen Andersen Elyard
SRSujatha Rashid
Sujatha Rashid
DYDavid Yarmosh
David Yarmosh
NPNikhita Puthuveetil
Nikhita Puthuveetil
SOShelby O'Connor
Shelby O'Connor
SARS-CoV-2 pathogenesis, vaccine, and therapeutic studies rely on the use of animals challenged with highly pathogenic virus stocks produced in cell cultures. Ideally, these virus stocks should be genetically and functionally similar to the original clinical isolate, retaining wild-type properties to be reliably used in animal model studies. It is well-established that SARS-CoV-2 isolates serially passaged on Vero cell lines accumulate mutations and deletions in the furin cleavage site; however, these can be eliminated when passaged on Calu-3 lung epithelial cell lines, as presented in this study. As numerous stocks of SARS-CoV-2 variants of concern are being grown in cell cultures with the intent for use in animal models, it is essential that propagation methods generate virus stocks that are pathogenic in vivo. Here, we found that the propagation of a B.1.351 SARS-CoV-2 stock on Calu-3 cells eliminated viruses that previously accumulated mutations in the furin cleavage site. Notably, there were alternative variants that accumulated at the same nucleotide positions in virus populations grown on Calu-3 cells at multiple independent facilities. When a Calu-3-derived B.1.351 virus stock was used to infect hamsters, the virus remained pathogenic and the Calu-3-specific variants persisted in the population. These results suggest that Calu-3-derived virus stocks are pathogenic but care should still be taken to evaluate virus stocks for newly arising mutations during propagation.

11 March 2024 in Viruses
Verified
Journal Article
Open access
PDF file
RCRyan Connor
Ryan Connor
MSMigun Shakya
Migun Shakya
DYDavid Yarmosh
David Yarmosh
WMWolfgang Maier
Wolfgang Maier
RMRoss Martin
Ross Martin
KPKim D Pruitt
Kim D Pruitt
Genomic sequencing of clinical samples to identify emerging variants of SARS-CoV-2 has been a key public health tool for curbing the spread of the virus. As a result, an unprecedented number of SARS-CoV-2 genomes were sequenced during the COVID-19 pandemic, which allowed for rapid identification of genetic variants, enabling the timely design and testing of therapies and deployment of new vaccine formulations to combat the new variants. However, despite the technological advances of deep sequencing, the analysis of the raw sequence data generated globally is neither standardized nor consistent, leading to vastly disparate sequences that may impact identification of variants. Here, we show that for both Illumina and Oxford Nanopore sequencing platforms, downstream bioinformatic protocols used by industry, government, and academic groups resulted in different virus sequences from same sample. These bioinformatic workflows produced consensus genomes with differences in single nucleotide polymorphisms, inclusion and exclusion of insertions, and/or deletions, despite using the same raw sequence as input datasets. Here, we compared and characterized such discrepancies and propose a specific suite of parameters and protocols that should be adopted across the field. Consistent results from bioinformatic workflows are fundamental to SARS-CoV-2 and future pathogen surveillance efforts, including pandemic preparation, to allow for a data-driven and timely public health response.

6 August 2026 in Parasite Immunology
Verified
Journal Article
Closed access
SMShamim Mohammad
Shamim Mohammad
IBIoana Brasov
Ioana Brasov
SGSusan Gottshall
Susan Gottshall
SRSarah Robins
Sarah Robins
SRSujatha Rashid
Sujatha Rashid
RMRobert E. Molestina
Robert E. Molestina